IOIV
Extension of Red Blood Cells' Shelf Life
Health Tech & Life Sciences
Non Active, Sep 2018
Company Overview
Snapshot
Founded in January 2016 by Tom Givaty Katz, Tal Ofek, Rawan Omar, and Sofia Arshavsky-Graham, IOIV operates with 1–10 employees. The company is currently in a Pre-Funding stage.
Business overview
IOIV is developing a novel additive solution designed to extend the shelf life of packed red blood cells while preserving their quality. This B2B solution aims to minimize the wastage of expired blood donations and enhance the quality of transfused blood. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries, with applications for healthcare providers and medical products.
Log in to access full profile ›Company Intelligence Q&A
- What is IOIV's primary focus?
- IOIV is focused on developing an additive solution to extend the shelf life of packed red blood cells, aiming to preserve their quality and reduce waste.
- When was IOIV founded?
- IOIV was founded in January 2016.
- Who are the founders of IOIV?
- IOIV was co-founded by Tom Givaty Katz, Tal Ofek, Rawan Omar, and Sofia Arshavsky-Graham.
- What industries does IOIV target?
- IOIV targets the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development, serving healthcare providers and the medical products industry.
- What is the current status of IOIV?
- IOIV is currently in a Non-Active status as of September 2018, and is in the Pre-Funding stage.